Samyang Biopharmaceuticals Corp. successfully launched its anti-cancer treatment drug Azacitidine Injection in the EU for the first time as a Korean company, according to the Samyang Group’s biomedical affiliate in January. Samyang Group, a South Korean food and chemicals producer, aims to manage 30% of its total assets overseas by 2025, while fostering nutrition, medical and eco-friendly materials as its core business for future, its chairman said.
“In order to cope with the new normal era in which uncertainty is deepening, we need to focus on reorganizing our core businesses and enhancing our execution capabilities,” Samyang Group Chairman Kim Yoon told employees in an online meeting on Aug. 2.
“To reinforce specialty business, we have to intensively nurture health and wellness sectors by expanding nutrition, medical and personal care business,” Kim said. “We will also make rapid inroads into eco-friendly business with successful commercialization of biodegradable plastic material isosorbide and recycling.”
Samyang aims to generate 60% or more of the group’s total operating profit from those specialty products, while operating 30% of the total assets globally, Kim said without elaboration.
We use cookies to provide the best user experience. By continuing to browse this website, you will be considered to accept cookies. Please review our Privacy Policy to learn our cookie policy.